Articles

Dr. R. S. Thakur
Email: drramsthakur@gmail.com

About Authors
Jatin Malik1, Rafael Balana Fouce2, Chandra Sekhar Venkata Gowri Kondapalli3, Murugesan Sankaranarayanan*1
¹Medicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Vidya Vihar, Pilani-333031, Rajasthan, India. 
²Department of Biomedical Sciences, Faculty of Veterinary Medicine, University of Leon, Leon, Spain-24071.

Operation TrialBlazer is a coordinated, department-wide initiative launched by the US Department of Health and Human Services (HHS) on June 22, 2026, aimed at restoring America's leadership in clinical research.

Redness, pain at the injection site, fever, fatigue and headache are some of the common temporary reactions that can occur after vaccination. However, not everyone experiences these effects in the same way. While some people may develop noticeable symptoms after vaccination, others may experience little or no reaction at all.

New research from the Center for Vaccinology at the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) has identified a possible biological explanation for these differences.

A new study published in The BMJ has found that adults with type 2 diabetes who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), may face a higher risk of developing non-scarring hair loss (alopecia) compared with patients taking other commonly prescribed diabetes medicines.

People living with diabetes and advanced chronic kidney disease (CKD) may benefit significantly from automated insulin delivery (AID) technology, according to a new international clinical trial. Researchers found that AID systems improved blood glucose control without increasing the risk of severe hypoglycaemia, offering a promising treatment option for one of the most medically complex diabetes populations.

India's manufacturing footprint is expanding, biosimilars are gaining momentum, and FDA inspections are evolving. The latest U.S. pharmaceutical quality report offers important insights for Indian manufacturers, exporters, regulators, and pharmacy professionals.

The question that hit our mind is, why are so many drug samples failing quality tests in india? Is it normal or does the pharmaceutical industry need to improve?